CDC25C (Ab-216) Antibody

What is CDC25C and why is Ser216 phosphorylation significant?

CDC25C is a dual-specificity phosphatase that represents a rate-limiting regulator of the G2/M-phase transition. The phosphorylation of Ser216 constitutes a well-conserved inhibitory modification that mediates DNA damage-induced G2/M arrest . This phosphorylation event initiates a cascade of events including binding to 14-3-3 proteins, cytoplasmic sequestration, and inhibition of CDC25C's ability to activate CDC2-cyclin B complexes . The Ser216 site serves as a critical integration point for multiple checkpoint pathways, ensuring cells with damaged DNA do not prematurely enter mitosis .

Which kinases phosphorylate CDC25C at Ser216?

Several kinases can phosphorylate CDC25C at Ser216 in different biological contexts:

• AMPK (AMP-activated protein kinase) directly phosphorylates CDC25C at Ser216 as demonstrated by in vitro kinase assays using recombinant proteins and confirmed by antibody recognition patterns .

• CHK1 and CHK2 checkpoint kinases target Ser216 during DNA damage responses .

• Other kinases may also target this site in response to various cellular stresses, creating a convergent regulatory mechanism for cell cycle control .

The phosphorylation by AMPK links energy metabolism to cell cycle control, while CHK1/CHK2-mediated phosphorylation connects DNA damage sensing to mitotic entry inhibition .

What is the specificity of CDC25C (Ab-216) Antibody?

The CDC25C (Ab-216) Antibody specifically detects endogenous levels of CDC25C protein phosphorylated at Ser216 . This antibody was generated using a synthetic peptide corresponding to amino acids 214-218 (S-P-S-M-P) of human CDC25C . Specificity for the phosphorylated form has been demonstrated through phosphatase treatment experiments, where treatment with calf intestinal alkaline phosphatase (CIAP) abolishes antibody recognition, confirming its phospho-specificity .

What applications is CDC25C (Ab-216) Antibody validated for?

According to manufacturer specifications, the CDC25C (Ab-216) Antibody has been validated for the following applications:

In published research, phospho-CDC25C (Ser216) antibodies have been successfully employed for immunohistochemical analysis of clinical cancer specimens, demonstrating utility in translational research contexts .

How can I verify the specificity of CDC25C (Ab-216) Antibody in my experiments?

To rigorously validate antibody specificity, researchers should implement multiple complementary approaches:

• Phosphatase treatment: Incubating protein samples with calf intestinal alkaline phosphatase (CIAP) should eliminate detection by truly phospho-specific antibodies, as demonstrated in published studies .

• Site-directed mutagenesis: Creating Ser216 to Alanine (S216A) mutants provides an excellent negative control, as this mutation abolishes the phosphorylation site . In published work, S216A mutants migrate as a single band with mobility corresponding to the lower band of the CDC25C doublet, providing further validation of antibody specificity .

• Sibling antibody comparison: Using antibodies that detect total CDC25C versus phospho-specific antibodies can provide complementary information and validation .

• Knockout/knockdown controls: CDC25C-depleted samples serve as critical negative controls to identify any cross-reactivity with related phosphatases or nonspecific signals .

How does CDC25C subcellular localization correlate with its phosphorylation at Ser216?

CDC25C subcellular localization is intricately linked to its phosphorylation status:

• Unphosphorylated CDC25C primarily localizes to the nucleus where it can activate CDC2-cyclin B complexes .

• Phosphorylation at Ser216 creates binding sites for 14-3-3 proteins, leading to cytoplasmic sequestration and functional inactivation .

• In cancer tissues, the relationship between phosphorylation and localization can be complex. Studies in vulvar carcinomas found that while total CDC25C was exclusively cytoplasmic in 63% of cases, phospho-CDC25C (Ser216) was detected in both cytoplasm (50%) and nucleus (70%) of samples . This unexpected nuclear localization of phosphorylated CDC25C in cancer may represent dysregulation of normal checkpoint mechanisms.

• During cell cycle progression and in response to stresses, the dynamic shuttling between compartments provides temporal and spatial regulation of CDC25C activity .

What are the methodological differences when detecting phospho-CDC25C (Ser216) in cell lines versus tissues?

Detection of phospho-CDC25C (Ser216) requires different methodological approaches depending on the experimental system:

For tissue applications, careful optimization of fixation protocols and antigen retrieval methods is essential to preserve phospho-epitopes while maintaining tissue morphology .

How should I interpret multiple bands when immunoblotting with CDC25C (Ab-216) Antibody?

Multiple bands in Western blots may represent:

• Phospho-isoforms: CDC25C exists in multiple phosphorylation states. Research has demonstrated that wild-type CDC25C typically appears as a doublet, while S216A mutants migrate as a single band corresponding to the lower band of the doublet . This confirms that the upper band represents Ser216-phosphorylated CDC25C.

• Splice variants: CDC25C has multiple splice variants that may be detected differentially.

• Proteolytic fragments: CDC25C undergoes regulated proteolysis during apoptosis and other cellular processes.

To distinguish between these possibilities:

• Compare molecular weights (expect ~60 kDa for full-length CDC25C)

• Perform phosphatase treatment to collapse phospho-isoforms

• Use siRNA knockdown to confirm band specificity

• Compare patterns with total CDC25C antibodies

Why might phospho-CDC25C (Ser216) levels not correlate with total CDC25C expression?

Discrepancies between total and phosphorylated CDC25C levels can arise from several mechanisms:

• Independent regulation of protein stability: Studies have shown that CDC25C protein degradation can occur independent of its phosphorylation status at Ser216. For example, Mdm2 can promote CDC25C degradation regardless of Ser216 phosphorylation state .

• Cell cycle-dependent fluctuations: While total CDC25C levels remain relatively stable throughout the cell cycle, the phosphorylation at Ser216 is dynamically regulated, particularly during G2/M transition and in response to DNA damage .

• Subcellular compartmentalization: Phosphorylated CDC25C may be sequestered in specific cellular compartments, affecting extraction efficiency and detection .

• Rapid phosphorylation kinetics: Following stress, phosphorylation can occur rapidly while protein levels change more slowly .

These observations highlight the importance of analyzing both total and phosphorylated forms when studying CDC25C regulation in experimental systems.

How is phospho-CDC25C (Ser216) analysis used in cancer research?

Phospho-CDC25C (Ser216) analysis has emerged as a valuable tool in cancer research:

• As a prognostic biomarker: In vulvar carcinomas, high phospho-CDC25C (Ser216) expression correlates with aggressive clinicopathological features including high FIGO stage, large tumor diameter, deep invasion, and poor differentiation . In univariate analysis, high expression was associated with poor disease-specific survival (p = 0.04) .

• As an indicator of checkpoint status: Abnormal patterns of CDC25C phosphorylation may indicate checkpoint dysfunction in cancer cells .

• For understanding drug mechanisms: Many chemotherapeutic agents and radiation therapy induce DNA damage that activates checkpoints involving CDC25C phosphorylation .

• In molecular classification: The pattern of CDC25C expression and phosphorylation may help stratify tumors into molecular subtypes with different clinical behaviors .

What is the significance of CDC25C Ser216 phosphorylation in AMPK signaling pathways?

The identification of CDC25C as a direct AMPK substrate establishes a mechanistic link between cellular energy status and cell cycle control:

• Metabolic regulation of cell cycle: AMPK senses cellular energy status and directly phosphorylates CDC25C at Ser216, thereby inhibiting cell cycle progression under energy stress conditions .

• Pharmacological implications: AMPK activators like AICAR and possibly metformin may exert their anti-proliferative effects partly through CDC25C inhibition . Both pharmacological and genetic activation of AMPK enhance Ser216 phosphorylation in CDC25C .

• Cancer metabolism connection: Cancer cells often exhibit altered metabolism and AMPK signaling. Understanding how these changes affect CDC25C regulation may provide insights into cancer cell proliferation mechanisms .

The direct regulation of CDC25C by AMPK represents a checkpoint mechanism that coordinates cell division with cellular energy status, ensuring cells don't attempt division under unfavorable metabolic conditions .

How does CDC25C (Ab-216) Antibody help distinguish between checkpoint activation and adaptation?

The CDC25C (Ab-216) Antibody provides a valuable tool for distinguishing between initial checkpoint activation and checkpoint adaptation or recovery:

• Initial checkpoint activation: Acute DNA damage or stress rapidly increases Ser216 phosphorylation while total CDC25C levels remain unchanged .

• Sustained checkpoint: Prolonged stress maintains high phospho-CDC25C (Ser216) levels but may eventually lead to transcriptional repression of CDC25C .

• Checkpoint adaptation: During adaptation, cells may bypass the checkpoint despite persistent damage. This state may be characterized by decreased phospho-CDC25C (Ser216) despite the presence of damage signals .

• Checkpoint recovery: Normal recovery after damage repair shows coordinated dephosphorylation of Ser216 and restoration of nuclear CDC25C activity .

By monitoring phospho-CDC25C (Ser216) in relation to total CDC25C levels, cell cycle markers, and DNA damage indicators, researchers can gain insights into checkpoint dynamics and potential dysregulation in cancer and other diseases .